UroStream

At the 2026 European Association of Urology Congress (EAU26), held in London, major advances in urologic oncology were presented. Among them, the work of Professor Xuesong Li’s team from Peking University First Hospital attracted considerable attention. The team not only contributed important achievements in upper urinary tract reconstruction but also presented a phase II clinical study of disitamab vedotin combined with radiotherapy for upper tract urothelial carcinoma (UTUC), offering a promising new treatment option.

At the 2026 European Association of Urology (EAU) Annual Congress held in London, leading experts from around the world gathered to discuss the latest advances and evolving clinical practices in genitourinary oncology. During the meeting, Oncology Frontier had the privilege of interviewing Professor Fred Saad from the Centre Hospitalier de l’Université de Montréal, who shared key insights into his team’s latest research, major breakthroughs in prostate cancer, and future therapeutic directions.

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded, delivering multiple landmark advances that are reshaping clinical practice in urologic oncology.

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) brought together cutting-edge advances and landmark studies in genitourinary oncology from around the world.

Upper tract urothelial carcinoma (UTUC) is an aggressive malignancy of the urinary system, with high-risk subtypes associated with substantial risks of recurrence, metastasis, and poor prognosis. For decades, radical nephroureterectomy has been the standard treatment for high-risk UTUC. However, this approach inevitably leads to irreversible renal function impairment and may even result in renal failure, significantly compromising long-term quality of life.

At the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU 2026), one of the world’s leading academic platforms in genitourinary oncology, Professor Jeremy Teoh (Yuan-Jin Zhang) and his team from The Chinese University of Hong Kong presented a series of landmark studies on en bloc resection of bladder tumor (ERBT). Backed by high-level evidence, these findings have positioned ERBT at the forefront of innovation in non–muscle-invasive bladder cancer (NMIBC), laying a solid clinical foundation for transforming treatment strategies.

With ongoing advances in research, combinations of targeted therapy and immunotherapy have become the standard first-line treatment for advanced urothelial carcinoma. However, upper tract urothelial carcinoma (UTUC) differs significantly from bladder cancer in terms of anatomical structure, pathological characteristics, prognosis, and recurrence risk. As a result, radical nephroureterectomy (RNU) remains the gold standard for non-metastatic UTUC.

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded. As one of the premier global academic meetings in genitourinary oncology, the conference showcased multiple landmark studies that are reshaping clinical practice worldwide.

As hematologic malignancy treatment advances toward precision medicine and cellular therapy, relapsed/refractory mixed phenotype acute leukemia (MPAL) remains a major clinical challenge due to its rarity and aggressive nature.

At the 52nd EBMT Annual Meeting held in Madrid in March 2026, the team led by Prof. Zhang Yajing presented a novel therapeutic approach targeting one of the most challenging clinical scenarios in hematology—early relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).